• Defactinib: FAK Phosphorylation Workflow

  2026-09-30

  Build a target-engagement workflow around Defactinib by pairing FAK Tyr397 phosphorylation measurements with viability, invasion, and paclitaxel-response endpoints. This practical framework helps distinguish pathway inhibition from nonspecific toxicity in ovarian cancer research and broader cancer therapy research.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  2026-09-29

  PP 3 is a research use only chemical that provides a concentration-matched negative-control arm for PP 2 experiments rather than another pathway inhibitor. This workflow applies ROS–calcium signaling findings from a vascular study to distinguish Src-associated interpretations from downstream L-type calcium-channel effects.

• Selective Spectrophotometry of Phenolic β-Lactams

  2026-09-29

  Salem and Saleh developed two selective spectrophotometric procedures for measuring four phenolic β-lactam antibiotics after oxidation with Ce(IV) or Fe(III) in acidic medium. The methods produced a shared yellow chromophore, enabling routine analysis of pure drugs and pharmaceutical formulations without relying on automated chromatographic systems.

• Fasudil (HA-1077) HCl: ROCK Translation

  2026-09-28

  A translational framework for using Fasudil (HA-1077) HCl as a ROCK inhibitor while connecting Rho/ROCK pathway inhibition with the pathway-validation logic emerging from Hippo signaling research in cataract models.

• Thiazovivin (A5506): Practical ROCK Inhibitor Guide

  2026-09-28

  Thiazovivin is a ROCK inhibitor used in workflows where researchers need to support fibroblast reprogramming or human embryonic stem cell survival after trypsinization. This guide covers product handling and experimental setup while distinguishing dossier specifications from protocol variables that must be established for each cell model; it is for research use, not clinical or diagnostic use.

• DDX21–NAT10 Signaling Drives CRC Metastasis

  2026-09-27

  A 2025 study links DDX21 to colorectal cancer metastasis and angiogenesis through competitive binding with SIRT7, transcriptional activation of NAT10, and increased ac4C modification of selected mRNAs. The findings identify a connected protein–chromatin–RNA stability pathway, while leaving its clinical and model-specific relevance to be established in further studies.

• Cordycepin–PDT Triggers Pyroptosis in Breast Cancer Cells

  2026-09-26

  A 2026 pre-proof study reports that cordycepin combined with photodynamic therapy (PDT) suppresses breast cancer cell growth and promotes pyroptosis associated with ROS accumulation, NLRP3 signaling, caspase-1, and GSDMD. Its inhibitor experiments support a role for oxidative stress and caspase-1, while leaving important questions about treatment parameters, pathway specificity, and in vivo relevance for follow-up studies.

• Morin in Bench Research: Workflows and Use Cases

  2026-09-26

  Use Morin to investigate oxidative stress, inflammation, podocyte energy metabolism, and aluminum-dependent fluorescence in controlled bench assays. A practical workflow pairs careful DMSO handling with orthogonal biological readouts—and keeps a clinical neuroleptic malignant syndrome case in its proper role as a lesson in measurement, not evidence of Morin treatment.

• Influenza Hemagglutinin (HA) Peptide in IP Workflows

  2026-09-25

  Use this competitive HA tag peptide to release HA-tagged proteins from antibody-based immunoprecipitation while preserving a route to analyze interaction partners. A practical workflow connects the peptide’s elution role to gastric-cancer signaling studies, with pilot parameters and troubleshooting guidance clearly distinguished from published findings.

• G418 Sulfate for RCC Cell Engineering

  2026-09-25

  Use Geneticin to establish and maintain neomycin-resistant renal cancer models for controlled studies of TFEB and PD-L1. This workflow connects reliable antibiotic selection with the key experimental questions raised by research on mTOR inhibitor resistance—without confusing selection with the tumor biology being tested.

• miR-18a–ALOXE3 Axis in Glioblastoma

  2026-09-24

  The study identifies ALOXE3 as a suppressor of glioblastoma growth, linking its loss to both resistance to p53–SLC7A11-dependent ferroptosis and increased migration. It further places miR-18a upstream of ALOXE3 and connects ALOXE3 silencing to 12-HETE-driven signaling, suggesting that lipid metabolism can influence distinct malignant traits in GBM.

• Capsaicin: An Exposure-Aware Guide to Target Attribution

  2026-09-24

  Capsaicin is both a TRPV1 activator and a reversible KDM1A/LSD1 inhibitor, so a cellular phenotype may have more than one explanation. This guide shows how exposure, target engagement, and orthogonal evidence can sharpen interpretation across sensory-neuron and gastric-cancer research.

• Acetylcysteine as a Redox Stress-Test in PDT

  2026-09-23

  Acetylcysteine (N-acetyl-L-cysteine, NAC) can serve as more than a generic antioxidant control: in photodynamic therapy research, it provides a practical perturbation for testing whether ROS accumulation is causally connected to pyroptotic cell death. This article translates recent cordycepin–PDT findings into an experimental strategy for oxidative stress pathway modulation, model selection, and translational decision-making.

• IL-17A and Neonatal GBS Risk: Study Insights

  2026-09-22

  A prospective Moroccan mother–newborn study identifies reduced maternal IL-17A, IL-1β, and IL-4 responses among GBS-colonized women whose infants developed invasive disease. The findings position maternal IL-17A as a promising risk-stratification biomarker while highlighting the value of functional ex vivo TLR1/2 and TLR4 stimulation alongside colonization testing.

• Forskolin: Adenylate Cyclase Activator Guide

  2026-09-22

  Forskolin is a direct adenylate cyclase activator that raises intracellular cAMP and supports controlled pathway perturbation in cellular assays. B1421 has documented applications in inflammation, stem-cell biology, hormone-release studies, and cardiovascular disease research, but its effects remain model- and condition-dependent.

8750 records 1/584 page Next 12345 下5页 Last page